Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 3/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.39 |
| ▸ | CDC25B | P30305 | 5/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174263 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL13112800 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL13956209 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL16027502 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL12407911 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL1087871 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL18511226 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL22129916 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL22330780 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 | |
| SCHEMBL13956220 | 1.00 | BCHE (0.56) | BCHEACHEHTR1ALMNATACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57154196-A | — | — | None | — | — | JP | disclosed |
| EP-4717316-A2 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | AbbVie Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-12324812-B2 | Glucopyranosyl derivatives and their uses | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250170263-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-29 | — | — | US | disclosed |
| CN-119306684-A | Key intermediate for preparing SGLTs inhibitor and preparation method thereof | 宜昌东阳光长江药业股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-1553094-A1 | AZULENE DERIVATIVES AND SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050124555-A1 | Azulene derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-0260121-B1 | INOSOSE DERIVATIVES, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
| EP-0240175-B1 | INOSOSE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-5004838-A | Inosose derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4898986-A | Inosose derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4824943-A | Inosose derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0260121-A2 | Inosose derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0240175-A1 | Inosose derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-10-07 | — | — | EP | disclosed |
| JP-S57154196-A | PREPARATION OF GLYCOSYLIDENE ACETALS | YOSHIMURA TOSHITSUGU | 1982-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170263-A1 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | EGFR, ERBB3, ERBB2 | BCHE 1409/4885ACHE 4603/4885HTR1A 4011/4885 |
| US-20050124555-A1 | Azulene derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | BCHE 3675/4885ACHE 4737/4885HTR1A 2526/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | BCHE 2479/4885ACHE 4793/4885HTR1A 3825/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | BCHE 2479/4885ACHE 4793/4885HTR1A 3825/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | BCHE 2479/4885ACHE 4793/4885HTR1A 3825/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | BCHE 3784/4885ACHE 4652/4885HTR1A 4520/4885 |
| US-12324812-B2 | Glucopyranosyl derivatives and their uses | SLC5A1, SLC5A2, UGGT1 | BCHE 3608/4885ACHE 3875/4885HTR1A 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.